Nonalcoholic steatohepatitis (NASH) liver fibrosis is the new golden goose in the biotech space. More than 40 companies are taking part in clinical trials to bring the first NASH drug to market. Very few of them are close to seeing some success. NASH’s market value is set to increase to $21.5 billion by 2025.
Full article
Full article